Gilead’s Remdesivir, the Drug that Could Treat Covid-19

Squawk Pod

CNBC

Business News, News, Investing, Business

4.2 • 543 Ratings

🗓️ 1 May 2020

⏱️ 37 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Gilead CEO Daniel O’Day shares details of Remdesivir’s two positive trials against Covid-19. He explains collaboration among global drugmakers, the process of finding a treatment for coronavirus, and worldwide, equitable distribution of the drug once it’s developed. CNBC’s Senior Health Science Reporter Meg Tirrell traces the history of Remdesivir, as well as the world’s response to pandemics in the past. In a conversation exclusive to Squawk Pod, Tirrell tracks the drugmakers still in the race for a Covid vaccine and treatment, and she explains covering the pandemic accurately amid rapidly evolving headlines.

Transcript

Click on a timestamp to play from that location

0:00.0	This is Guacck Pot. I'm C. NBC producer Katie Kramer. Today on our
0:05.2	podcast, The Drug that could help treat COVID-19, Remdesifir, and the drug
0:10.4	maker behind it. Gillyad CEO Daniel O'Day on the promising early stage results of the drugs trials.
0:16.3	On behalf of all the colleagues at Gilead that have been working day and night, we're just
0:20.3	humbled and pleased by the results this week
0:22.6	of the starting point for therapies.
0:24.7	How Gilead is working with other drug makers
0:26.8	to quite literally save the world.
0:28.8	Oftentimes, combinations of medicines
0:31.0	is exactly one needs to take the next step in terms of treatments. And the detail. of sure on a global basis that this medicine gets into the patients that need it.
0:45.6	Plus, Podcast Exclusive, going beyond the COVID headlines with the
0:48.8	CNBC reporter who's covered it for months, Meg Turrell.
0:51.8	Gile had developed this drug years ago,
0:55.0	so it's been kind of a long tale, a month's long story
0:58.0	to get to this point.
0:59.0	This could be the first drug proven to really work
1:02.0	against COVID-19.
1:03.0	It's Friday, May 1st, 2020, May Day, Squawk Pod begins right after this.
1:11.0	You're listening to Squawk Pod from CNBC.
1:17.0	Today's highlight interview is with Gilead CEO Daniel O'Day.
1:21.0	Gilead is the maker of the antiviral remdesifir that might, might, be effective
1:26.9	in treating COVID-19. Will it work? There's a lot to understand about the pharmaceutical
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from CNBC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of CNBC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.